Role of Burkholderia pseudomallei–Specific IgG2 in Adults with Acute Melioidosis, Thailand
Panjaporn Chaichana, Kemajittra Jenjaroen, Suchintana Chumseng, Manutsanun Sumonwiriya, Patpong Rongkard, Barbara Kronsteiner, Prapit Teparrukkul, Direk Limmathurotsakul, Nicholas P.J. Day, Narisara Chantratita, and Susanna J Dunachie
Author affiliations: Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand (P. Chaichana, K. Jenjaroen, S. Chumseng, M. Sumonwiriya, P. Rongkard, D. Limmathurotsakul, N.P.J. Day, N. Chantratita, S.J. Dunachie); University of Oxford, Oxford, England (P. Rongkard, B. Kronsteiner, D. Limmathurotsakul, N.P.J. Day, S. Dunachie); Sunpasithiprasong Hospital, Ubon Ratchathani, Thailand (P. Teparrukkul)
Main Article
Table 2
Multivariable-adjusted logistic regression for melioidosis mortality rates, Thailand*
Variable |
Mortality rate
|
Adjusted OR (95% CI) |
p value
|
Serum IgG2 level |
0.50 (0.30–0.83) |
0.007 |
Age >45 y |
0.36 (0.10–1.30) |
0.120 |
Diabetes |
0.92 (0.34–2.53) |
0.876 |
Preexisting renal disease
|
9.41 (2.48–35.80)
|
0.001
|
Neutrophil count/µL |
|
|
>4,000–8,000 |
Referent |
<0.001 |
<4,000 |
4.66 (0.52–41.50) |
|
>8,000–12,000 |
19.00 (3.40–106.33) |
|
>12,000
|
14.78 (2.78–78.73)
|
|
*OR, odds ratio. |
Main Article
Page created: December 14, 2020
Page updated: January 23, 2021
Page reviewed: January 23, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.